Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and Pathological Responses in Borderline Resectable or Unresectable Stage III NSCLC By Ogkologos - June 3, 2025 336 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a multicentre cohort study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Clinical Trials in Genitourinary Cancers: CheckMate 914, KEYNOTE-992, and KEYNOTE-991 May 20, 2021 During No-Visitor Policy at Hospital, Surgeon Comforts Breast Cancer Patient Getting... April 14, 2020 Lack of Immunity Against SARS-CoV-2 in a Large Tertiary Care Centre... September 2, 2020 News digest – light-activated nanoparticles, Government’s obesity plans, tumour ‘glue’ and... July 11, 2020 Load more HOT NEWS Rebuilding My Life After Cancer and Intensive Treatment: A Survivor’s Story Trial Suggests Expanded Role for Blinatumomab in Treating ALL David Dangoor: “Education is a treasure that you give someone and... Early-onset cancer: why are more young adults being diagnosed?
